The signaling lipid sphingosine-1-phosphate (S1P) plays critical roles in mammalian biology. The concentration of S1P is high in blood, and plasma S1P stabilizes junctions between vascular endothelial cells. The concentration of S1P is low in lymphoid tissues compared to blood and lymph, and S1P compartmentalization is required to maintain proper lymphocyte circulation. Although S1P in lymphoid organs is low in homeostasis, the concentration of S1P may increase upon inflammation, and increases in tissue S1P have been reported to promote angiogenesis and to enhance pro-inflammatory responses of innate and adaptive immune cells. Drugs targeting S1P signaling and S1P metabolism are currently in clinical trials as immune suppressants. By blocking lymphocyte exit from lymphoid organs, these drugs prevent activated T cells from reaching transplanted organs or organs that are subject to autoimmune attack. These drugs may also have direct anti-inflammatory effects. Despite S1P's vital functions, little is understood about how its distribution is controlled. To maintain low tissue S1P, two sources must be contained. First, tissues are constantly bathed with plasma to bring nourishment and remove waste. Plasma S1P must be prevented from entering, or removed from, the organs. Second, all cells are thought to make S1P intracellularly during the course of membrane sphingolipid metabolism. This intracellular S1P must be destroyed before it is secreted into the interstitial space. This grant investigates how S1P concentrations in the lymphoid organs are regulated.

Public Health Relevance

Drugs targeting sphingosine-1-phosphate (S1P) receptors and S1P metabolic enzymes are in clinical trials as immune suppressants. There is an urgent need to understand how S1P distribution is controlled both to design improved therapies and to anticipate potential side-effects.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Cellular and Molecular Immunology - B Study Section (CMIB)
Program Officer
Dong, Gang
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York University
Schools of Medicine
New York
United States
Zip Code
Dixit, Dhaval; Schwab, Susan R (2018) PreB cells are moving on. J Exp Med 215:2483-2484
Mendoza, Alejandra; Fang, Victoria; Chen, Cynthia et al. (2017) Lymphatic endothelial S1P promotes mitochondrial function and survival in naive T cells. Nature 546:158-161
Fang, Victoria; Chaluvadi, V Sai; Ramos-Perez, Willy D et al. (2017) Gradients of the signaling lipid S1P in lymph nodes position natural killer cells and regulate their interferon-? response. Nat Immunol 18:15-25
Pitt, Lauren A; Tikhonova, Anastasia N; Hu, Hai et al. (2015) CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance. Cancer Cell 27:755-68
Baeyens, Audrey; Fang, Victoria; Chen, Cynthia et al. (2015) Exit Strategies: S1P Signaling and T Cell Migration. Trends Immunol 36:778-787
Ramos-Perez, Willy D; Fang, Victoria; Escalante-Alcalde, Diana et al. (2015) A map of the distribution of sphingosine 1-phosphate in the spleen. Nat Immunol 16:1245-52
Diehl, Gretchen E; Longman, Randy S; Zhang, Jing-Xin et al. (2013) Microbiota restricts trafficking of bacteria to mesenteric lymph nodes by CX(3)CR1(hi) cells. Nature 494:116-20
Mendoza, Alejandra; Bréart, Béatrice; Ramos-Perez, Willy D et al. (2012) The transporter Spns2 is required for secretion of lymph but not plasma sphingosine-1-phosphate. Cell Rep 2:1104-10
Cyster, Jason G; Schwab, Susan R (2012) Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol 30:69-94
Bréart, Béatrice; Ramos-Perez, Willy D; Mendoza, Alejandra et al. (2011) Lipid phosphate phosphatase 3 enables efficient thymic egress. J Exp Med 208:1267-78